Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate.
Lone Z, Benidir T, Rainey M, Nair M, Davicioni E, Gibb EA, Williamson S, Gupta S, Chaim Ornstein M, Tendulkar R, Weight C, Nguyen JK, Klein EA, Mian OY. Lone Z, et al. Among authors: mian oy. Eur Urol Focus. 2022 Nov;8(6):1575-1582. doi: 10.1016/j.euf.2022.05.005. Epub 2022 May 31. Eur Urol Focus. 2022. PMID: 35662504
Molecular Characterization of Neuroendocrine-like Bladder Cancer.
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Batista da Costa J, et al. Among authors: mian oy. Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5. Clin Cancer Res. 2019. PMID: 30952638
Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.
Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y. Grivas P, et al. Among authors: mian oy. Urol Oncol. 2020 Apr;38(4):262-268. doi: 10.1016/j.urolonc.2019.11.004. Epub 2019 Dec 4. Urol Oncol. 2020. PMID: 31812633
Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.
Tom MC, Reddy CA, Smile TD, Zhang RX, Ciezki JP, Stephans KL, Mian OY, Klein EA, Campbell S, Ulchaker J, Angermeier K, Tendulkar RD. Tom MC, et al. Among authors: mian oy. Brachytherapy. 2020 Jan-Feb;19(1):43-50. doi: 10.1016/j.brachy.2019.10.005. Epub 2019 Dec 5. Brachytherapy. 2020. PMID: 31813740
Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable.
Tendulkar RD, Mian OY. Tendulkar RD, et al. Among authors: mian oy. Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):238. doi: 10.1016/j.ijrobp.2019.07.016. Int J Radiat Oncol Biol Phys. 2020. PMID: 31928637 No abstract available.
Management of Oligometastatic Prostate Cancer.
Broughman JR, Fleming CW, Mian OY, Stephans KL, Tendulkar RD. Broughman JR, et al. Among authors: mian oy. Appl Radiat Oncol. 2020 Sep;9(3):6-10. Epub 2020 Sep 9. Appl Radiat Oncol. 2020. PMID: 33134438 Free PMC article. No abstract available.
62 results